RBC Capital raised the firm’s price target on Addus HomeCare (ADUS) to $139 from $134 and keeps an Outperform rating on the shares. The company reported solid Q3 results, driven by strong 6.6% organic growth in Personal Care and should be well positioned to capitalize on additional M&A opportunities, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus HomeCare price target raised to $140 from $139 at TD Cowen
- Addus HomeCare Reports Strong Q3 2025 Results
- Addus Homecare: Strategic Growth and Strong Financial Performance Justify Buy Rating
- Addus HomeCare Q3 2025 Earnings: Growth Amid Challenges
- Addus HomeCare price target raised to $117 from $111 at Barclays
